GLP1R and hydrops fetalis: Furthermore, results from the phase III STEP-HFpEF and STEP-HFpEF DM trials demonstrated that weekly subcutaneous injections of 2.4 mg semaglutide significantly reduced HF-related symptoms and physical limitations while improving exercise capacity in obese HFpEF patients, suggesting potential expansion of cardiovascular indications for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (Kosiborod et al., 2023; Kosiborod et al., 2024).